These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

859 related articles for article (PubMed ID: 10861043)

  • 1. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Feb; 164(3):1200-10. PubMed ID: 10640731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
    Delgado M; Ganea D
    J Immunol; 2001 Jan; 166(2):1028-40. PubMed ID: 11145682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VIP and PACAP inhibit Fas ligand-mediated bystander lysis by CD4(+) T cells.
    Delgado M; Ganea D
    J Neuroimmunol; 2001 Jan; 112(1-2):78-88. PubMed ID: 11108936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VIP and PACAP inhibit activation induced apoptosis in T lymphocytes.
    Delgado M; Ganea D
    Ann N Y Acad Sci; 2000; 921():55-67. PubMed ID: 11193880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression.
    Delgado M; Leceta J; Gomariz RP; Ganea D
    J Immunol; 1999 Oct; 163(7):3629-35. PubMed ID: 10490956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression.
    Delgado M; Sun W; Leceta J; Ganea D
    J Immunol; 1999 Oct; 163(8):4213-23. PubMed ID: 10510358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.
    Ganea D; Delgado M
    Crit Rev Oral Biol Med; 2002; 13(3):229-37. PubMed ID: 12090463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
    Delgado M; Ganea D
    J Immunol; 2000 Sep; 165(6):3051-7. PubMed ID: 10975815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo.
    Aung S; Graham BS
    J Immunol; 2000 Apr; 164(7):3487-93. PubMed ID: 10725701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
    J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
    Delgado M; Ganea D
    J Immunol; 2001 Jul; 167(2):966-75. PubMed ID: 11441105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fas ligand (CD95L) protects neurons against perforin-mediated T lymphocyte cytotoxicity.
    Medana I; Li Z; Flügel A; Tschopp J; Wekerle H; Neumann H
    J Immunol; 2001 Jul; 167(2):674-81. PubMed ID: 11441070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ECH, an epoxycyclohexenone derivative that specifically inhibits Fas ligand-dependent apoptosis in CTL-mediated cytotoxicity.
    Mitsui T; Miyake Y; Kakeya H; Osada H; Kataoka T
    J Immunol; 2004 Mar; 172(6):3428-36. PubMed ID: 15004142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages.
    Sun W; Tadmori I; Yang L; Delgado M; Ganea D
    J Neuroimmunol; 2000 Jul; 107(1):88-99. PubMed ID: 10808055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.